James Blome, the CEO of Bayer Crop Science, said in a video released Monday morning that if Bayer AG’s $62 billion deal for Monsanto is approved the headquarters for joint crop science efforts would be in St. Louis.

Currently, Bayer Crop Science bases its U.S. operations in Research Triangle Park.

“Bayer’s new global Seeds & Traits and North American commercial headquarters would be based in Missouri,” Blome said in discussing what he saw as the benefits of the proposed Bayer-Monsanto merger.

Monsanto is based in St. Louis.

Darren Wallace, vice rpesident of communications for Bayer, pointed out in a statement, however, that Bayer remains commited to RTP.

“Under the proposed transaction of Bayer and Monsanto, the global seeds and traits and North American commercial headquarters will be in St. Louis,” Wallis said. “The combined company will continue to maintain a significant presence in RTP.”

Bayer AG, the parent of Bayer Crop Science, disclosed its formal offer for Monsanto early Monday.

Bayer Crop Science division has about 700 employees in RTP and another 300 at related sites in Clayton, Morrisville and Pikeville. The division has made capital investments in the Triangle totaling about $150 million since 2012.

Added facilities include greenhouses, a renovated office complex and a North American Bee Care Center that supports product stewardship, sustainable agricultural and comprehensive solutions for honey bee health.

Monsanto also has operations in North Carolina.

Blome said a combined company would “continue to have an important presence in North Carolina.”

“The Digital Farming for the combined business would be based in California,” he added.

  • More coverage: Read the full transcript of Blome’s video

Overall, the corporate combination would create a giant seed and farm chemical company with a strong presence in the U.S., Europe and Asia.

Bayer said the all-cash offer values shares of Monsanto at $122 each. That compares with a closing price Friday of $101.52 and is 37 percent higher than the closing price of $89.03 on May 9, the day before Bayer made a written proposal to Monsanto.

Bayer had said on Thursday that its executives met recently with their Monsanto counterparts “to privately discuss a negotiated acquisition” of the specialist in genetically modified crop seeds, which is headquartered in St. Louis, Missouri. Monsanto said then that it was reviewing Bayer’s proposal.

Bayer said it plans to finance the acquisition with a combination of debt and equity, the latter to be raised largely by issuing new shares. Bayer’s shares, which tumbled after the initial announcement last week, dropped 3.1 percent in early Frankfurt trading Monday to 86.78 euros ($97.37). Monsanto shares jumped 11.3 percent to $112.98 in pre-market trading.

The German company said that it “is prepared to proceed immediately to due diligence and negotiations and to quickly agree to a transaction.”

“Monsanto is a perfect match to our agricultural business,” Bayer CEO Werner Baumann said in a video message posted on his company’s website. “We would combine complementary skills with minimal geographic overlap.”

“The acquisition of Monsanto checks all the boxes in terms of strategic fit and value creation potential,” he added. “At the same time, ongoing consolidation activities in the industry make this combination by far the most attractive one.”

Baumann said Bayer expects the transaction to “create significant synergies” and bolster earnings in the first full year after it is completed.

Both companies are familiar brands on farms around the globe. Bayer’s farm business produces seeds as well as compounds to kill weeds, bugs and fungus.

Monsanto has some 20,000 employees and produces seeds for fruits, vegetables and other crops including corn, soybeans and cotton, as well as the popular weed-killer Roundup.

Bayer, headquartered in Leverkusen, Germany, employs some 117,000 people worldwide.